A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of this study is to evaluate bioavailability of lanadelumab (SHP643) following a single, 2 milliliter (mL) subcutaneous (SC) dose of 300 milligrams (mg) delivered by prefilled syringe (PFS) or auto injector (AI) in healthy adult participants.
Epistemonikos ID: ef73156746ddfc9f4ad32caa727b52cf93f443c0
First added on: May 22, 2024